Pascal and Francis Bibliographic Databases

Help

Search results

Your search

ti.\*:("The pharmacokinetics of cilostazol")

Results 1 to 12 of 12

  • Page / 1
Export

Selection :

  • and

The pharmacokinetics of cilostazolCREAGER, Mark A.Clinical pharmacokinetics. 1999, Vol 37, issn 0312-5963, 98 p., SUP2Serial Issue

Effect of omeprazole on the metabolism of cilostazolSURI, A; BRAMER, S. L.Clinical pharmacokinetics. 1999, Vol 37, pp 53-59, issn 0312-5963, SUP2Article

Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolitesMALLIKAARJUN, S; FORBES, W. P; BRAMER, S. L et al.Clinical pharmacokinetics. 1999, Vol 37, pp 33-40, issn 0312-5963, SUP2Article

Effects of CYP3A inhibition on the metabolism of cilostazolSURI, A; FORBES, W. P; BRAMER, S. L et al.Clinical pharmacokinetics. 1999, Vol 37, pp 61-68, issn 0312-5963, SUP2Article

Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarinMALLIKAARJUN, S; BRAMER, S. L.Clinical pharmacokinetics. 1999, Vol 37, pp 79-86, issn 0312-5963, SUP2Article

Interaction potential and tolerability of the coadministration of cilostazol and aspirinMALLIKAARJUN, S; FORBES, W. P; BRAMER, S. L et al.Clinical pharmacokinetics. 1999, Vol 37, pp 87-93, issn 0312-5963, SUP2Article

Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazolBRAMER, S. L; SURI, A.Clinical pharmacokinetics. 1999, Vol 37, pp 41-51, issn 0312-5963, SUP2Article

Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokineticsBRAMER, S. L; FORBES, W. P.Clinical pharmacokinetics. 1999, Vol 37, pp 13-23, issn 0312-5963, SUP2Article

Effect of multiple cilostazol doses on single dose Lovastatin pharmacokinetics in healthy volunteersBRAMER, S. L; BRISSON, J; COREY, A. E et al.Clinical pharmacokinetics. 1999, Vol 37, pp 69-77, issn 0312-5963, SUP2Article

Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazolBRAMER, S. L; FORBES, W. P.Clinical pharmacokinetics. 1999, Vol 37, pp 25-32, issn 0312-5963, SUP2Article

Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy SubjectsYOO, H.-D; PARK, S.-A; CHO, H.-Y et al.Clinical pharmacology and therapeutics. 2009, Vol 86, Num 3, pp 281-284, issn 0009-9236, 4 p.Article

Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial diseaseBRAMER, S. L; FORBES, W. P; MALLIKAARJUN, S et al.Clinical pharmacokinetics. 1999, Vol 37, pp 1-11, issn 0312-5963, SUP2Article

  • Page / 1